RESEARCH TRIANGLE PARK - G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that additional findings from a Phase 2 clinical trial demonstrating the myelopreservation benefits of trilaciclib in 2nd/3rd-line small cell lung cancer (SCLC) patients will be featured as an oral presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
The presentation will take place on June 1, 2019 at 3:00 p.m. CT at the McCormick Place Convention Center in Chicago, Illinois.
Trilaciclib is a first-in-class myelopreservation agent designed to protect the bone marrow from damage by chemotherapy and improve patient outcomes.
'Chemotherapy remains an important treatment in the fight against cancer, however it has serious side effects, including damaging the patient's bone marrow. We are pleased to present further findings that show the addition of trilaciclib to chemotherapy can protect the bone marrow from damage in those undergoing treatment for SCLC,' said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D. 'We look forward to our pre-NDA and pre-MAA meetings later this year with U.S. and European regulatory authorities as we work to bring trilaciclib to market for SCLC patients and continue to explore how trilaciclib may help those with other types of cancer.'
Details on the presentation are listed below and are also available on the 2019 ASCO Annual Meeting website: http://abstracts.asco.org/.
Title: Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.
Abstract Number: 8505
Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Date and Time: Saturday, June 1, 2019, 3:00-3:15 p.m. CT
Location: Hall D2, McCormick Place Lakeside Center Level 3
Presenter: Lowell Hart., M.D., Scientific Director of Research, Florida Cancer Specialists
Trilaciclib is a first-in-class myelopreservation agent designed to protect the bone marrow from damage by chemotherapy and improve patient outcomes. G1 plans to submit marketing applications in the U.S. and Europefor trilaciclib for myelopreservation in SCLC in 2020. These submissions will be based on currently available data from three randomized, double-blind, placebo-controlled SCLC clinical trials, as well as safety data collected across all completed and ongoing clinical trials.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib and lerociclib are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the therapeutic potential of trilaciclib, lerociclib and G1T48 and the timing for next steps with regard to the trilaciclib marketing applications, and are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including the 'Risk Factors' sections contained therein and include, but are not limited to, the Company's ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the Company's initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; the Company's development of a CDK4/6 inhibitor to reduce chemotherapy-induced myelosuppression is novel, unproven and rapidly evolving and may never lead to a marketable product and market conditions. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.